Roux, C <br/><br/>
Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.  [electronic resource] 

 -  Bone  Jan 2014 
 - 48-54 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-2763 
<br/><br/><label>Standard No.: </label>10.1016/j.bone.2013.10.006  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Alendronate--therapeutic use<br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Bone Density--drug effects<br/>Bone Density Conservation Agents--adverse effects<br/>Collagen Type I--blood<br/>Demography<br/>Denosumab<br/>Etidronic Acid--analogs & derivatives<br/>Female<br/>Humans<br/>Medication Adherence<br/>Osteoporosis, Postmenopausal--blood<br/>Peptides--blood<br/>Risedronic Acid<br/>Treatment Outcome